Background and Objectives: Kidney transplant recipients are at risk of developing more severe forms of COVID-19 infection. The aim of this study was to compare the clinical course of COVID-19 infection among kidney transplant patients and a control group. Materials and Methods: We examined 150 patients hospitalized with COVID-19 infection. Patients were divided into study (kidney transplant recipients, n = 53) and control (without a history of kidney transplantation, n = 97) groups. Demographics, clinical characteristics, treatment data, and clinical outcomes were assessed. Results: The median patient age was 56.0 (46.0–64.0) years, and seventy-seven patients (51.3%) were men. The median Charlson comorbidity index was higher in the study group (3.0 vs. 2.0, p < 0.001). There was a higher incidence of hypoxemia in the control group upon arrival (52.6% vs. 22.6%, p = 0.001) and a higher NEWS index median (2.0 vs. 1.0 points, p = 0.009) and incidence of pneumonia during hospitalization (88.7% vs. 73.6%, p = 0.023). In the study group, there were more cases of mild (26.4% vs. 11.3%, p = 0.023) and critically severe forms of COVID-19 infection (26.4% vs. 3.1%, p < 0.001), kidney failure was more prevalent (34.0% vs. 1.0%, p < 0.001), and a greater number of patients were transferred to the intensive care unit (22.6% vs. 3.1%, p < 0.001) and died (18.9% vs. 1.0%, p < 0.001). Multivariable analysis revealed that treatment in the intensive care unit correlated with a higher mortality rate than transplantation itself (HR = 20.71, 95% CI 2.01–213.33, p = 0.011). Conclusions: The course of the COVID-19 disease in kidney transplant recipients is heterogeneous and can be more severe than in the general population. Even though patients may be hospitalized with fewer symptoms, complications and death are more likely to occur.
A 6‐year‐old male patient with pulmonary atresia and recent valve replacement with a Melody valve presented with a 6‐week history of fever and cough. He was diagnosed with Coxiella burnetii endocarditis based on a C. burnetii Phase I IgG antibody titre of 1:65,536 and increased metabolic activity surrounding his prosthetic cardiac valve on positron emission tomography scan. Treatment was initiated with doxycycline and hydroxychloroquine. However, despite dose escalation, target plasma concentrations were not achieved. The patient experienced rapid clinical improvement, and serological markers declined gradually. Antimicrobial therapy was discontinued after 40 months, as predefined serological criteria were met, clinical course was favourable, and a follow‐up positron emission tomography scan demonstrated a significant reduction in metabolic activity around the prosthetic valve. Up to 23 months after cessation of therapy, the patient showed no evidence of active C. burnetii endocarditis during follow‐up. The Melody valve maintained its function, and valve replacement was not required. Clinicians should employ an individualised treatment approach to children with C. burnetii endocarditis.